Evidence map›Paper›PMID 23540678›Full record

ArticleJournal of medicinal chemistry2013

Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats.

Yong Liu, Janell Richardson, Thao Tran, Nour Al-Muhtasib, Teresa Xie, Venkata Mahidhar Yenugonda, Hannah G Sexton, Amir H Rezvani, Edward D Levin, Niaz Sahibzada and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Yong LiuCenter for Drug Discovery, Georgetown University Medical Center , Research Building EP07, 3970 Reservoir Road, NW, Washington, DC 20057, United States.
Janell Richardson
Thao Tran
Nour Al-Muhtasib
Teresa Xie
Venkata Mahidhar Yenugonda
Hannah G Sexton
Amir H Rezvani
Edward D Levin
Niaz Sahibzada
Kenneth J Kellar
Milton L Brown
Yingxian Xiao
Mikell Paige
Georgetown University · USDuke Medical Center · USDuke University Hospital · USGeorgetown University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Rodents with Genetic Differences in Alcohol PreferenceR24AA015512 · NIAAA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BELL, RICHARD LOWELL · 2005 to 2014
$5.1M
Synthesis and Optimization of Selective alpha4beta2 Neuronal nAChR DesensitizersU19DA027990 · NIDA · GEORGETOWN UNIVERSITY · PI LEVIN, EDWARD D · 2010 to 2014
$4.3M
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug AbuseR03DA025947 · NIDA · GEORGETOWN UNIVERSITY · PI PAIGE, MIKELL · 2009 to 2010
$467k
High Throughput Screening for nAChRs: Cell Lines and Assay DevelopmentR21DA032489 · NIDA · GEORGETOWN UNIVERSITY · PI XIAO, YINGXIAN · 2011 to 2011
$243k
NCI NIH HHS P30 CA051008NCI NIH HHS P30-CA051008NIAAA NIH HHS NIH- R24AA015512NIAAA NIH HHS R24 AA015512NIDA NIH HHS R03 DA025947NIDA NIH HHS R03DA025947NIDA NIH HHS R21 DA032489NIDA NIH HHS R21DA032489NIDA NIH HHS U19 DA027990NIDA NIH HHS U19DA027990
6 · The paper itself

Abstract

Neuronal acetylcholine receptors mediate the addictive effects of nicotine and may also be involved in alcohol addiction. Varenicline, an approved smoking cessation medication, showed clear efficacy in reducing alcohol consumption in heavy-drinking smokers. More recently, sazetidine-A, which selectively desensitizes α4β2 nicotinic receptors, was shown to significantly reduce alcohol intake in a rat model. To develop novel therapeutics for treating alcohol use disorder, we designed and synthesized novel sazetidine-A analogues containing a methyl group at the 2-position of the pyridine ring. In vitro pharmacological studies revealed that some of the novel compounds showed overall pharmacological property profiles similar to that of sazetidine-A but exhibited reduced agonist activity across all nicotinic receptor subtypes tested. In rat studies, compound (S)-9 significantly reduced alcohol uptake. More importantly, preliminary results from studies in a ferret model indicate that these novel nAChR ligands have an improved adverse side-effect profile in comparison with that of varenicline.

Indexed as

Alcohol DrinkingAnimalsEthanolFerretsLigandsMagnetic Resonance SpectroscopyPyridinesRatsReceptors, NicotinicSpectrometry, Mass, Electrospray IonizationEthanolLigandsnicotinic receptor alpha4beta2PyridinesReceptors, Nicotinic

Identifiers

PMID23540678
PMCPMC3809750
OpenAlexW2064221775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.